“The Sentinel System complements our current adjunctive TAVR offerings which include the Safari2 Guidewire, the iSleeve Expandable Sheath and the Bolt Direct Access Sheath,” Trish Backes, a company spokesperson for Boston Scientific, told HCB News at the time. “While the Sentinel System is indicated for use only with TAVR procedures in the U.S, Boston Scientific will pursue opportunities for the system to be used more broadly as the CE Mark label indicates, in other endovascular procedures like mitral valve repair and replacement, LAAC, and pulmonary vein isolation (PVI) ablation procedures for Afib.”

Prior to this purchase, rumors arose in June around Boston Scientific regarding an alleged takeover bid by Stryker with the news initially reported by The Wall Street Journal.


Stryker denied to the Journal at the time that it was in any such discussions with Boston Scientific.

“Stryker is not in discussions with Boston Scientific Corporation regarding a potential acquisition," the company said in an SEC filing at the time.

"The filing from Stryker states that the company is not in discussions with Boston Scientific. It does not deny that prior discussions took place," Jason Benowitz, senior portfolio manager at Roosevelt Investment Group, told the Star Tribune at the time. However, "putting together a deal for Boston Scientific that creates value for Stryker shareholders would be a challenging high-wire act."

The VICI system is considered investigational at present and is not yet for sale in North America. No similar peripheral venous stent systems are currently available in the U.S.

Back to HCB News

Business Affairs Homepage